AstraZeneca Links Up With Targacept In $1.2B Deal
U.K. drugmaker AstraZeneca PLC has entered into an agreement worth up to $1.24 billion to join efforts with U.S. biotech firm Targacept Inc. in developing an experimental drug to treat depression....To view the full article, register now.
Already a subscriber? Click here to view full article